Adults with overweight or obesity who take incretin-based therapies have a lower risk of dying from any cause compared to those who do not, based on combined data from multiple studies.

Medications that target incretin hormones do not raise the likelihood of low blood sugar or pancreatitis in adults who are overweight or obese.

Medications that target incretin hormones lower the risk of illness and death in people with diabetes by improving how the body processes glucose and functions of the heart and blood vessels.

Medications called incretin-based therapies, used for type 2 diabetes, are associated with better heart health due to their effects on reducing inflammation, lowering blood pressure, and helping with weight loss.

Medicines like semaglutide and tirzepatide help people lose a lot of weight—up to a quarter of their body weight—but they also cause some muscle loss, about as much as you’d normally lose in 10 years of aging.